Cargando…
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
AIMS: To assess the cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab added to standard-of-care lipid-lowering treatment [maximum tolerated dose (MTD) of statin and ezetimibe] in Swedish patients with a history of myocardial infarction (MI). METHODS AND R...
Autores principales: | Landmesser, Ulf, Lindgren, Peter, Hagström, Emil, van Hout, Ben, Villa, Guillermo, Pemberton-Ross, Peter, Arellano, Jorge, Svensson, Maria Eriksson, Sibartie, Mahendra, Fonarow, Gregg C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728027/ https://www.ncbi.nlm.nih.gov/pubmed/33063111 http://dx.doi.org/10.1093/ehjqcco/qcaa072 |
Ejemplares similares
-
Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia
por: Peng, Yanren, et al.
Publicado: (2022) -
Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
por: Wu, Qingyu, et al.
Publicado: (2022) -
Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
por: Suur, Bianca E., et al.
Publicado: (2022) -
Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
por: Melendez, Quantil M., et al.
Publicado: (2020) -
Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022)